HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment

A meta-analysis and systematic review

Yun Zhang, Bangtao Chen, Lin Wang, Junjie Chi, Shaojuan Song, Mingshe Liu, Z. Zhao

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background and aims: Seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is generally considered as a clinical endpoint. The purpose of the present meta-analysis was to evaluate the effect of combined therapy with pegylated interferon alpha (PEG-IFNα) with or without lamivudine (LAM) or adefovir (ADV) on HBsAg seroclearance or seroconversion in subjects with chronic hepatitis B (CHB). Methods: Randomized controlled trials performed through May 30th 2015 in adults with CHB receiving PEG-IFNα and LAM or ADV combination therapy or monotherapy for 48-52 weeks were included. The Review Manager Software 5.2.0 was used for the meta-analysis. Results: No statistical differences in HBsAg seroclearance (9.9% vs. 7.1%, OR = 1.47, 95% CI: 0.75, 2.90; p = 0.26) or HBsAg seroconversion (4.2% vs. 3.7%, OR = 1.17, 95% CI: 0.57, 2.37; p = 0.67) rates were noticed between PEG-IFNα+ LAM and PEG-IFN α+ placebo during post-treatment follow-up for 24-26-weeks in subjects with hepatitis Be antigen (HBeAg)-positive CHB. No statistical differences in HBsAg clearance (10.5% vs. 6.4%, OR = 1.68, 95% CI: 0.75, 3.76; p = 0.21) were seen, but statistical differences in HBsAg seroconversion (6.3% vs. 0%, OR = 7.22, 95% CI: 1.23, 42.40; p = 0.03) were observed, between PEG-IFNα+ ADV and PEG-IFNα for 48-52 weeks of treatment in subjects with HBeAg-positive CHB. A systematic evaluation showed no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM for 48-52 weeks in subjects with HBeAg-positive CHB. A systematic assessment found no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM during 24 weeks’ to 3 years’ followup after treatment in subjects with HBeAg-negative CHB. Conclusion: Combined therapy with PEG-IFNα and LAM or ADV was not superior to monotherapy with PEG-IFNα in terms of HBsAg seroclearance or seroconversion.

Original languageEnglish
Pages (from-to)263-270
Number of pages8
JournalRevista Espanola de Enfermedades Digestivas
Volume108
Issue number5
Publication statusPublished - May 1 2016

Fingerprint

Chronic Hepatitis B
Hepatitis B Surface Antigens
Interferon-alpha
Meta-Analysis
Lamivudine
Hepatitis B e Antigens
Therapeutics
Placebos
lamivudine-adefovir combination
Seroconversion
Software
Randomized Controlled Trials

Keywords

  • Adefovir
  • Chronic hepatitis B
  • Combination therapy
  • Hepatitis B surface antigen
  • Lamivudine
  • Peginterferon alpha

ASJC Scopus subject areas

  • Gastroenterology

Cite this

HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment : A meta-analysis and systematic review. / Zhang, Yun; Chen, Bangtao; Wang, Lin; Chi, Junjie; Song, Shaojuan; Liu, Mingshe; Zhao, Z.

In: Revista Espanola de Enfermedades Digestivas, Vol. 108, No. 5, 01.05.2016, p. 263-270.

Research output: Contribution to journalReview article

@article{9ab01e0e839d4963a705fd17a3c7077a,
title = "HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: A meta-analysis and systematic review",
abstract = "Background and aims: Seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is generally considered as a clinical endpoint. The purpose of the present meta-analysis was to evaluate the effect of combined therapy with pegylated interferon alpha (PEG-IFNα) with or without lamivudine (LAM) or adefovir (ADV) on HBsAg seroclearance or seroconversion in subjects with chronic hepatitis B (CHB). Methods: Randomized controlled trials performed through May 30th 2015 in adults with CHB receiving PEG-IFNα and LAM or ADV combination therapy or monotherapy for 48-52 weeks were included. The Review Manager Software 5.2.0 was used for the meta-analysis. Results: No statistical differences in HBsAg seroclearance (9.9{\%} vs. 7.1{\%}, OR = 1.47, 95{\%} CI: 0.75, 2.90; p = 0.26) or HBsAg seroconversion (4.2{\%} vs. 3.7{\%}, OR = 1.17, 95{\%} CI: 0.57, 2.37; p = 0.67) rates were noticed between PEG-IFNα+ LAM and PEG-IFN α+ placebo during post-treatment follow-up for 24-26-weeks in subjects with hepatitis Be antigen (HBeAg)-positive CHB. No statistical differences in HBsAg clearance (10.5{\%} vs. 6.4{\%}, OR = 1.68, 95{\%} CI: 0.75, 3.76; p = 0.21) were seen, but statistical differences in HBsAg seroconversion (6.3{\%} vs. 0{\%}, OR = 7.22, 95{\%} CI: 1.23, 42.40; p = 0.03) were observed, between PEG-IFNα+ ADV and PEG-IFNα for 48-52 weeks of treatment in subjects with HBeAg-positive CHB. A systematic evaluation showed no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM for 48-52 weeks in subjects with HBeAg-positive CHB. A systematic assessment found no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM during 24 weeks’ to 3 years’ followup after treatment in subjects with HBeAg-negative CHB. Conclusion: Combined therapy with PEG-IFNα and LAM or ADV was not superior to monotherapy with PEG-IFNα in terms of HBsAg seroclearance or seroconversion.",
keywords = "Adefovir, Chronic hepatitis B, Combination therapy, Hepatitis B surface antigen, Lamivudine, Peginterferon alpha",
author = "Yun Zhang and Bangtao Chen and Lin Wang and Junjie Chi and Shaojuan Song and Mingshe Liu and Z. Zhao",
year = "2016",
month = "5",
day = "1",
language = "English",
volume = "108",
pages = "263--270",
journal = "Revista Espanola de Enfermedades Digestivas",
issn = "1130-0108",
publisher = "ARAN Ediciones S.A.",
number = "5",

}

TY - JOUR

T1 - HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment

T2 - A meta-analysis and systematic review

AU - Zhang, Yun

AU - Chen, Bangtao

AU - Wang, Lin

AU - Chi, Junjie

AU - Song, Shaojuan

AU - Liu, Mingshe

AU - Zhao, Z.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background and aims: Seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is generally considered as a clinical endpoint. The purpose of the present meta-analysis was to evaluate the effect of combined therapy with pegylated interferon alpha (PEG-IFNα) with or without lamivudine (LAM) or adefovir (ADV) on HBsAg seroclearance or seroconversion in subjects with chronic hepatitis B (CHB). Methods: Randomized controlled trials performed through May 30th 2015 in adults with CHB receiving PEG-IFNα and LAM or ADV combination therapy or monotherapy for 48-52 weeks were included. The Review Manager Software 5.2.0 was used for the meta-analysis. Results: No statistical differences in HBsAg seroclearance (9.9% vs. 7.1%, OR = 1.47, 95% CI: 0.75, 2.90; p = 0.26) or HBsAg seroconversion (4.2% vs. 3.7%, OR = 1.17, 95% CI: 0.57, 2.37; p = 0.67) rates were noticed between PEG-IFNα+ LAM and PEG-IFN α+ placebo during post-treatment follow-up for 24-26-weeks in subjects with hepatitis Be antigen (HBeAg)-positive CHB. No statistical differences in HBsAg clearance (10.5% vs. 6.4%, OR = 1.68, 95% CI: 0.75, 3.76; p = 0.21) were seen, but statistical differences in HBsAg seroconversion (6.3% vs. 0%, OR = 7.22, 95% CI: 1.23, 42.40; p = 0.03) were observed, between PEG-IFNα+ ADV and PEG-IFNα for 48-52 weeks of treatment in subjects with HBeAg-positive CHB. A systematic evaluation showed no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM for 48-52 weeks in subjects with HBeAg-positive CHB. A systematic assessment found no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM during 24 weeks’ to 3 years’ followup after treatment in subjects with HBeAg-negative CHB. Conclusion: Combined therapy with PEG-IFNα and LAM or ADV was not superior to monotherapy with PEG-IFNα in terms of HBsAg seroclearance or seroconversion.

AB - Background and aims: Seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is generally considered as a clinical endpoint. The purpose of the present meta-analysis was to evaluate the effect of combined therapy with pegylated interferon alpha (PEG-IFNα) with or without lamivudine (LAM) or adefovir (ADV) on HBsAg seroclearance or seroconversion in subjects with chronic hepatitis B (CHB). Methods: Randomized controlled trials performed through May 30th 2015 in adults with CHB receiving PEG-IFNα and LAM or ADV combination therapy or monotherapy for 48-52 weeks were included. The Review Manager Software 5.2.0 was used for the meta-analysis. Results: No statistical differences in HBsAg seroclearance (9.9% vs. 7.1%, OR = 1.47, 95% CI: 0.75, 2.90; p = 0.26) or HBsAg seroconversion (4.2% vs. 3.7%, OR = 1.17, 95% CI: 0.57, 2.37; p = 0.67) rates were noticed between PEG-IFNα+ LAM and PEG-IFN α+ placebo during post-treatment follow-up for 24-26-weeks in subjects with hepatitis Be antigen (HBeAg)-positive CHB. No statistical differences in HBsAg clearance (10.5% vs. 6.4%, OR = 1.68, 95% CI: 0.75, 3.76; p = 0.21) were seen, but statistical differences in HBsAg seroconversion (6.3% vs. 0%, OR = 7.22, 95% CI: 1.23, 42.40; p = 0.03) were observed, between PEG-IFNα+ ADV and PEG-IFNα for 48-52 weeks of treatment in subjects with HBeAg-positive CHB. A systematic evaluation showed no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM for 48-52 weeks in subjects with HBeAg-positive CHB. A systematic assessment found no differences in HBsAg disappearance and seroconversion rates between PEG-IFNα+ placebo and PEG-IFNα+ LAM during 24 weeks’ to 3 years’ followup after treatment in subjects with HBeAg-negative CHB. Conclusion: Combined therapy with PEG-IFNα and LAM or ADV was not superior to monotherapy with PEG-IFNα in terms of HBsAg seroclearance or seroconversion.

KW - Adefovir

KW - Chronic hepatitis B

KW - Combination therapy

KW - Hepatitis B surface antigen

KW - Lamivudine

KW - Peginterferon alpha

UR - http://www.scopus.com/inward/record.url?scp=84978643505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978643505&partnerID=8YFLogxK

M3 - Review article

VL - 108

SP - 263

EP - 270

JO - Revista Espanola de Enfermedades Digestivas

JF - Revista Espanola de Enfermedades Digestivas

SN - 1130-0108

IS - 5

ER -